DCB Combined with Provisional DES Implantation in the Treatment of De Novo Medina 0,1,0 or 0,0,1 Left Main Coronary Bifurcation Lesions: A Proof-of-concept Study

Overview

Journal Anatol J Cardiol

Publisher Kare Publishing

Specialty Cardiology & Vascular Diseases

Date 2022 Mar 29

PMID 35346908

Authors

Emrah Erdogan

Zheng Li

Yong-Xiang Zhu

Vincenzo Tufaro

Si-Li Feng

Qian Li

Li Liang

Shang Chang

Ling-Tong Bu

Bing Liu

Qi-Hua Zhou

Nathan A L Yap

Christos V Bourantas

Yao-Jun Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the safety and efficacy of a percutaneous revascularization strategy that is based on the use of drug-coated balloon for the treatment of patients with acute coronary syndrome and de novo Medina type 0,1,0 or 0,0,1 left main stem bifurcation lesions.

Methods: In this multicenter, prospective, proof-of-concept study, patients fulfilling the above criteria were enrolled and received treatment with drug-coated balloon combined with provisional drug-eluting stent implantation in the proximal major branches of the left main stem. Patients who declined this revascularization approach were treated with drug-eluting stent implantation 1-2 mm distally to the left anterior descending or left circumflex artery ostium followed by drug-coated balloon therapy for the ostial disease. The primary endpoint of the study was the calculation of percent diameter stenosis on quantitative coronary angiography post-procedure as well as event rate at 8 months follow-up.

Results: A total of 30 patients were enrolled in the study; their mean age was 60.3 ± 7.8 years, while 22 (73.3%) were male. Twenty-two patients were treated only with drugcoated balloon and provisional drug-eluting stent implantation and 8 had drug-eluting stent implantation followed by drug-coated balloon therapy of the ostium of the left main stem major branch. All the procedures were successful with no immediate complications. The percent diameter stenosis of lesion decreased significantly post-procedure from 87.5% (80.0-90.0) to 20% (17.5-30.0), P <.001. During the follow-up period, no major adverse cardiac events were reported.

Conclusions: This proof-of-concept study indicates that ostial drug-coated balloon therapy of the left main stem major branches is safe and effective. Larger clinical data and longer follow-up are needed before advocating its regular use in clinical practice.

Citing Articles

Composite outcomes of drug-coated balloon using in left main bifurcation lesions: a systematic review.

Cheng Y, Chen Y, Huang B, Chen M J Geriatr Cardiol. 2024; 21(11):1047-1059.

PMID: 39734648 PMC: 11672355. DOI: 10.26599/1671-5411.2024.11.001.

Stent, balloon and hybrid in PCI: could the whole be greater than the sum of its parts?.

Lim P Br J Cardiol. 2024; 30(4):37.

PMID: 39247419 PMC: 11376257. DOI: 10.5837/bjc.2023.037.

Single-Stent Double-Kissing Nano-Crush Technique for the Management of Side Branch Ostial Lesions: A Game Changer? Or Just Another Player in the Game?.

Yalta K Anatol J Cardiol. 2023; 27(10):611-612.

PMID: 37776105 PMC: 10541785. DOI: 10.14744/AnatolJCardiol.2023.3694.

Treatment of Peripheral Artery Disease Using Injectable Biomaterials and Drug-Coated Balloons: Safety and Efficacy Perspective.

Qamar S, Spahic L, Benolic L, Zivanovic M, Filipovic N Pharmaceutics. 2023; 15(7).

PMID: 37514000 PMC: 10385947. DOI: 10.3390/pharmaceutics15071813.

Nano-Culotte Stenting for Coronary Bifurcation Lesions: Pros and Cons of a Novel Strategy.

Yalta K Anatol J Cardiol. 2023; 27(5):290-291.

PMID: 37119191 PMC: 10160836. DOI: 10.14744/AnatolJCardiol.2023.3149.

References

Medina A, Martin P, Suarez de Lezo J, Amador C, de Lezo J, Pan M . Vulnerable carina anatomy and ostial lesions in the left anterior descending coronary artery after floating-stent treatment. Rev Esp Cardiol. 2009; 62(11):1240-9. DOI: 10.1016/s1885-5857(09)73351-1. View

Kleber F, Rittger H, Ludwig J, Schulz A, Mathey D, Boxberger M . Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol. 2016; 105(7):613-21. DOI: 10.1007/s00392-015-0957-6. View

Vranckx P, Cutlip D, Mehran R, Kint P, Silber S, Windecker S . Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010; 5(7):871-4. DOI: 10.4244/eijv5i7a146. View

Capranzano P, Sanfilippo A, Tagliareni F, Capodanno D, Monaco S, Sardella G . Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions. Am Heart J. 2010; 160(5):973-8. DOI: 10.1016/j.ahj.2010.07.002. View

Valgimigli M, Bueno H, Byrne R, Collet J, Costa F, Jeppsson A . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the.... Eur Heart J. 2017; 39(3):213-260. DOI: 10.1093/eurheartj/ehx419. View

Kwan T, James D, Huang Y, Liou M, Wong S, Coppola J . Perfection of precise ostial stent placement. J Invasive Cardiol. 2012; 24(7):354-8. View

Kornowski R . The complexity of stenting in bifurcation coronary lesions. JACC Cardiovasc Interv. 2013; 6(7):696-7. DOI: 10.1016/j.jcin.2013.04.005. View

Jeger R, Eccleshall S, Wan Ahmad W, Ge J, Poerner T, Shin E . Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020; 13(12):1391-1402. DOI: 10.1016/j.jcin.2020.02.043. View

Burzotta F, Lassen J, Lefevre T, Banning A, Chatzizisis Y, Johnson T . Percutaneous coronary intervention for bifurcation coronary lesions: the 15 consensus document from the European Bifurcation Club. EuroIntervention. 2020; 16(16):1307-1317. PMC: 8919527. DOI: 10.4244/EIJ-D-20-00169. View

10.

Kim B, Hong S, Cho Y, Yun K, Kim Y, Suh Y . Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020; 323(23):2407-2416. PMC: 7298605. DOI: 10.1001/jama.2020.7580. View

11.

Burzotta F, Talarico G, Trani C, De Maria G, Pirozzolo G, Niccoli G . Frequency-domain optical coherence tomography findings in patients with bifurcated lesions undergoing provisional stenting. Eur Heart J Cardiovasc Imaging. 2013; 15(5):547-55. DOI: 10.1093/ehjci/jet231. View

12.

Mehran R, Baber U, Sharma S, Cohen D, Angiolillo D, Briguori C . Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019; 381(21):2032-2042. DOI: 10.1056/NEJMoa1908419. View

13.

Liu Y, Zhang Y, Deng L, Yin Z, Hu T, Wang Q . 12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0 mm. Int J Cardiovasc Imaging. 2019; 35(4):579-586. DOI: 10.1007/s10554-018-1505-z. View

14.

Lansky A, Wijns W, Xu B, Kelbaek H, van Royen N, Zheng M . Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet. 2018; 392(10153):1117-1126. DOI: 10.1016/S0140-6736(18)31649-0. View

15.

Rigatelli G, Zuin M, Baracca E, Galasso P, Carraro M, Mazza A . Long-Term Clinical Outcomes of Isolated Ostial Left Anterior Descending Disease Treatment: Ostial Stenting Versus Left Main Cross-Over Stenting. Cardiovasc Revasc Med. 2019; 20(12):1058-1062. DOI: 10.1016/j.carrev.2019.01.030. View

16.

Her A, Ann S, Singh G, Kim Y, Okamura T, Garg S . Serial Morphological Changes of Side-Branch Ostium after Paclitaxel-Coated Balloon Treatment of De Novo Coronary Lesions of Main Vessels. Yonsei Med J. 2016; 57(3):606-13. PMC: 4800348. DOI: 10.3349/ymj.2016.57.3.606. View

17.

Murasato Y, Shibao K, Meno K, Takenaka K . A case of very late stent thrombosis on the protruded struts at the left main coronary bifurcation. J Cardiol Cases. 2020; 22(1):40-43. PMC: 7326694. DOI: 10.1016/j.jccase.2020.04.007. View

18.

Cayli M, Elbasan Z, Gur M, Seker T, Ucar H, Kuloglu O . Modified flower petal technique in the treatment of Medina type 0,0,1 or 0,1,0 lesions. EuroIntervention. 2015; 11(7):772-9. DOI: 10.4244/EIJV11I7A154. View

19.

Vaquerizo B, Fernandez-Nofreiras E, Oategui I, Suarez de Lezo J, Rumoroso J, Martin P . Second-Generation Drug-Eluting Balloon for Ostial Side Branch Lesions (001-Bifurcations): Mid-Term Clinical and Angiographic Results. J Interv Cardiol. 2016; 29(3):285-92. DOI: 10.1111/joic.12292. View

20.

Her A, Shin E, Bang L, Nuruddin A, Tang Q, Hsieh I . Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group. Cardiol J. 2019; 28(1):136-149. PMC: 8105061. DOI: 10.5603/CJ.a2019.0093. View